KAYLA FACUNDUS: Open Payments
NPI 1841784345 · CLACKAMAS, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,779 in 70 payments from 12 companies in 2025. Trend: 2023 $75 · 2024 $148 · 2025 $1,779
Food & beverage: $1,721Education: $59
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 19 | $411 |
| CSL Behring | 12 | $396 |
| Regeneron Healthcare Solutions, Inc. | 11 | $304 |
| Novartis Pharmaceuticals Corporation | 6 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $142 |
| Amgen Inc. | 7 | $135 |
| GlaxoSmithKline, LLC. | 5 | $123 |
| Genentech USA, Inc. | 1 | $27 |
| Blueprint Medicines Corporation | 1 | $26 |
| Pharming Healthcare, Inc. | 1 | $19 |
Products named: TEZSPIRE, DUPIXENT, Haegarda, AIRSUPRA, CUVITRU, Andembry, NUCALA, Hizentra.
Industry payments across OR — which companies pay providers there.
